drugset / Trial / NCT02521246

Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

NCT02521246

Phase 3 Withdrawn EMS
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Timeline

Start
2016-11
Primary completion
2017-05
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 16 mg
Subject Chlorthalidone Other / unclassified 12.5 mg
Subject Chlorthalidone Other / unclassified 25 mg
Comparator Hydrochlorothiazide Unknown 25 mg
Comparator Losartan Other / unclassified 100 mg